Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

By C. Vogel, M. Cobleigh, D. Tripathy, John C. Gutheil, Lyndsay N Harris, L. Fehrenbacher, D. Slamon, M. Murphy, William F Novotny, M. Burchmore and 3 more. Journal of Clinical Oncology, 2002

869 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/ffe43ab57cb77c267775fdce32136fafa56127a5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. N. Hynes
2. Ming Tan
3. F. McCormick
4. M. Hung
5. Michael R. Stratton
6. Joe W. Gray
7. Dihua Yu
8. G. Hortobagyi

In Pulmonary and Respiratory Medicine

1. N. Hynes

Citations in the corpus

• An Integrated Mechanistic Model of Pan-Cancer Driver Pathways Predicts Stochastic Proliferation and Death (2017, neutral): “In some cases, mutation-matched patients do not respond to the drug (Cobleigh et al., 1999), or alternatively, resistance stochastically develops (Vogel et al., 2002).”
• Drug penetration in solid tumours (2006, background): “by ∼50%, despite the fact that it leads to tumour response in only ∼25% of women with advanced metastatic diseas”
• Antibodies and cancer therapy: versatile platforms for cancer immunotherapy (2010, background): “Trastuzumab monotherapy showed a 35% objective response rate in patients with metastatic breast cancer not previously receiving chemotherap”
• Cancer heterogeneity—a multifaceted view (2013, neutral): “trastuzumab (an anti-HER2 monoclonal antibody; [78]) has cru-”